Antipsychotic Drugs Market by Class (First Generation, Second Generation, Third Generation), Indication (Bipolar Disorders, Dementia, Schizophrenia) - Global Forecast 2024-2030
Description
Antipsychotic Drugs Market by Class (First Generation, Second Generation, Third Generation), Indication (Bipolar Disorders, Dementia, Schizophrenia) - Global Forecast 2024-2030
The Antipsychotic Drugs Market size was estimated at USD 9.65 billion in 2023 and expected to reach USD 10.42 billion in 2024, at a CAGR 8.01% to reach USD 16.56 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Antipsychotic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antipsychotic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Antipsychotic Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes, Inc., AMBOSS GmbH, Amgen Inc, Arlak Biotech, AstraZeneca PLC, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories, Ltd., Eli Lilly and Company, Flagship Biotech International Pvt. Ltd., GlaxoSmithKline PLC, H. Lundbeck A/S, Johnson & Johnson Services Inc., Lifecare Neuro Products Ltd., Luye Pharma Group, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer, Inc., S. Karger AG, Seqirus Pty Ltd, Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries, Ltd., and Vanda Pharmaceuticals Inc..
Market Segmentation & Coverage
This research report categorizes the Antipsychotic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
Class
First Generation
Haldo
Geodon
Abilify
Bipolar Disorders
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Antipsychotic Drugs Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antipsychotic Drugs Market?
- What are the technology trends and regulatory frameworks in the Antipsychotic Drugs Market?
- What is the market share of the leading vendors in the Antipsychotic Drugs Market?
- Which modes and strategic moves are suitable for entering the Antipsychotic Drugs Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Antipsychotic Drugs Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing prevalence of psychosis and associated diseases
- 5.1.1.2. Rising drug approval from governments
- 5.1.1.3. Growing awareness regarding mental health and wellness
- 5.1.2. Restraints
- 5.1.2.1. Patent expiry of established brands
- 5.1.3. Opportunities
- 5.1.3.1. R&D and clinical trials for new antipsychotic drugs
- 5.1.3.2. Improvements in antipsychotic drug testing
- 5.1.4. Challenges
- 5.1.4.1. Stringent regulatory framework and compliance
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Antipsychotic Drugs Market, by Class
- 6.1. Introduction
- 6.2. First Generation
- 6.3.1. Haldo
- 6.3.2. Navane
- 6.3. Second Generation
- 6.4.1. Geodon
- 6.4.2. Invega
- 6.4.3. Latuda
- 6.4.4. Risperdal
- 6.4.5. Seroquel
- 6.4.6. Zyprexa
- 6.4. Third Generation
- 6.5.1. Abilify
- 7. Antipsychotic Drugs Market, by Indication
- 7.1. Introduction
- 7.2. Bipolar Disorders
- 7.3. Dementia
- 7.4. Schizophrenia
- 7.5. Unipolar Depression
- 8. Americas Antipsychotic Drugs Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
- 9. Asia-Pacific Antipsychotic Drugs Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
- 10. Europe, Middle East & Africa Antipsychotic Drugs Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
- 11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
- 12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. AbbVie Inc.
- 12.1.2. Alkermes, Inc.
- 12.1.3. AMBOSS GmbH
- 12.1.4. Amgen Inc
- 12.1.5. Arlak Biotech
- 12.1.6. AstraZeneca PLC
- 12.1.7. Bristol-Myers Squibb Company
- 12.1.8. Daiichi Sankyo Company, Limited
- 12.1.9. Dr. Reddy's Laboratories, Ltd.
- 12.1.10. Eli Lilly and Company
- 12.1.11. Flagship Biotech International Pvt. Ltd.
- 12.1.12. GlaxoSmithKline PLC
- 12.1.13. H. Lundbeck A/S
- 12.1.14. Johnson & Johnson Services Inc.
- 12.1.15. Lifecare Neuro Products Ltd.
- 12.1.16. Luye Pharma Group
- 12.1.17. Merck & Co., Inc.
- 12.1.18. Novartis AG
- 12.1.19. Otsuka Pharmaceutical Co. Ltd.
- 12.1.20. Pfizer, Inc.
- 12.1.21. S. Karger AG
- 12.1.22. Seqirus Pty Ltd
- 12.1.23. Sumitomo Dainippon Pharma Co., Ltd.
- 12.1.24. Teva Pharmaceutical Industries, Ltd.
- 12.1.25. Vanda Pharmaceuticals Inc.
- 12.2. Key Product Portfolio
- 13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
- FIGURE 1. ANTIPSYCHOTIC DRUGS MARKET RESEARCH PROCESS
- FIGURE 2. ANTIPSYCHOTIC DRUGS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ANTIPSYCHOTIC DRUGS MARKET DYNAMICS
- FIGURE 7. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
- FIGURE 8. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 10. ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
